Pay in 4 interest-free payments of $5.43 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
To address the issues of poor bioavailability and overall efficacy, researchers have sought to develop novel analogs of CU through structural modifications
N Engl J Med 316:775779
In contrast, Ultomiris failed to significantly improve event-free survival over placebo in adults and adolescents with HSCT-TMA, marking the latest setback for AstraZeneca's pipeline after a failed heart disease trial earlier this month and an FDA advisory committee voted against approving its breast cancer therapy in May
PubMed 15
Your physician can design a protocol that incorporates both compounds with appropriate timing and dosing
US$ 24.31
US$ 29.21
US$ 21.32
US$ 25.95
US$ 24.79
US$ 27.46
